Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
J Virol. 2012 Dec;86(24):13679-88. doi: 10.1128/JVI.02439-12. Epub 2012 Oct 10.
Elite controllers or suppressors (ES) are HIV-1-infected individuals who suppress viral replication to clinically undetectable levels without antiretroviral therapy. Understanding the mechanisms by which ES control viral replication may prove informative for the design of a therapeutic vaccine. Qualitative differences in the CD8(+) T cell response have been implicated in control. Therefore, we isolated CD8(+) T cells from ES and characterized the ability of sorted memory and activation subpopulations to control viral replication at various effector-to-target cell ratios using a novel modification of a CD8(+) T cell suppression assay. The effector memory and terminal effector subpopulations of memory CD8(+) T cells had the highest inhibitory potential over the course of a 3-day in vitro infection. Interestingly, after 5 days of infection, central memory CD8(+) T cells were also very effective at suppressing viral replication. No significant correlation between the suppression of viral replication and the number of HIV-1-specific CD8(+) T cells was observed. HLA-DR(-) CD38(+) CD8(+) T cells possessed the lowest inhibitory potential of the activation subpopulations. Taken together, our data suggest that there are key differences in the magnitude and kinetics of the suppression of HIV-1 replication by different CD8(+) T cell subsets. These data should guide the development of an effective, cellular therapeutic vaccine that has the potential to elicit similar CD8(+) T cell responses.
精英控制器或抑制剂 (ES) 是指在没有抗逆转录病毒治疗的情况下,将病毒复制抑制到临床无法检测水平的 HIV-1 感染者。了解 ES 控制病毒复制的机制可能有助于设计治疗性疫苗。CD8(+) T 细胞反应的定性差异与控制有关。因此,我们从 ES 中分离出 CD8(+) T 细胞,并使用一种新型 CD8(+) T 细胞抑制测定法的修改版,对分离出的记忆和激活亚群在不同效应细胞与靶细胞比值下控制病毒复制的能力进行了特征描述。在为期 3 天的体外感染过程中,记忆 CD8(+) T 细胞的效应记忆和终末效应亚群具有最高的抑制潜能。有趣的是,在感染 5 天后,中央记忆 CD8(+) T 细胞也非常有效地抑制病毒复制。未观察到病毒复制抑制与 HIV-1 特异性 CD8(+) T 细胞数量之间存在显著相关性。激活亚群中,HLA-DR(-) CD38(+) CD8(+) T 细胞的抑制潜能最低。综上所述,我们的数据表明,不同 CD8(+) T 细胞亚群对 HIV-1 复制的抑制程度和动力学存在关键差异。这些数据应指导开发有效的细胞治疗性疫苗,该疫苗具有诱导类似 CD8(+) T 细胞反应的潜力。